Kenneth Carl Anderson

Kenneth Carl Anderson


Prominent publications by Kenneth Carl Anderson

KOL Index score: 26546

BACKGROUND: As lenalidomide becomes increasingly established for upfront treatment of multiple myeloma, patients refractory to this drug represent a population with an unmet need. The combination of pomalidomide, bortezomib, and dexamethasone has shown promising results in phase 1/2 trials of patients with relapsed or refractory multiple myeloma. We aimed to assess the efficacy and safety of this triplet regimen in patients with relapsed or refractory multiple myeloma who previously ...

Also Ranks for: Dexamethasone Patients |  multiple myeloma |  pomalidomide bortezomib |  phase 3 |  received lenalidomide
KOL Index score: 25909

BACKGROUND: Isatuximab is a monoclonal antibody that binds a specific epitope on the human CD38 receptor and has antitumour activity via multiple mechanisms of action. In a previous phase 1b study, around 65% of patients with relapsed and refractory multiple myeloma achieved an overall response with a combination of isatuximab with pomalidomide and low-dose dexamethasone. The aim of this study was to determine the progression-free survival benefit of isatuximab plus pomalidomide and ...

Also Ranks for: 3 Study |  pomalidomide dexamethasone |  refractory multiple |  patients isatuximab |  monoclonal antibodies
KOL Index score: 25259

Increased angiogenesis has recently been recognized in active multiple myeloma (MM). Since vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) are two key mediators of angiogenesis, we characterized the production of VEGF, b-FGF and interleukin-6 (IL-6) (a MM growth and survival factor) in MM cell lines and Epstein–Barr virus (EBV) transformed B cell lines from MM patients, patient MM cells, as well as bone marrow stromal cells (BMSCs) from normal healthy ...

Also Ranks for: Mm Cells Bmscs |  growth factor |  vascular endothelial |  stromal cells |  il6 vegf
KOL Index score: 23159

BACKGROUND: Multiple myeloma is an incurable haematological malignancy, representing over 10% of haematological cancers in the USA. We did a phase 1-2 study of melflufen and dexamethasone in patients with relapsed and refractory multiple myeloma to determine the maximum tolerated dose of melflufen and to investigate its safety and efficacy.

METHODS: We did a multicentre, international, dose-confirmation and dose-expansion, open-label, phase 1-2 study in seven centres in the USA and ...

Also Ranks for: Multiple Myeloma |  melflufen patients |  combination dexamethasone |  single agent |  phase 2
KOL Index score: 22815

BACKGROUND: Bortezomib, lenalidomide, and dexamethasone (VRd) is a standard therapy for newly diagnosed multiple myeloma. Carfilzomib, a next-generation proteasome inhibitor, in combination with lenalidomide and dexamethasone (KRd), has shown promising efficacy in phase 2 trials and might improve outcomes compared with VRd. We aimed to assess whether the KRd regimen is superior to the VRd regimen in the treatment of newly diagnosed multiple myeloma in patients who were not being ...

Also Ranks for: Patients Vrd |  diagnosed multiple |  induction therapy |  lenalidomide dexamethasone |  phase 3
KOL Index score: 21272

Donor lymphocyte infusions (DLI) can induce remissions in patients who have relapsed after allogeneic bone marrow transplantation (BMT). However, DLI frequently also result in significant acute and/or chronic graft-versus-host disease (GVHD). Several clinical and experimental lines of evidence have suggested that CD8(+) T cells play a critical role in the pathogenesis of GVHD. To develop methods to reduce the incidence of GVHD associated with DLI, we administered defined numbers of ...

Also Ranks for: Gvhd Patients |  donor lymphocytes |  bone marrow |  allogeneic bmt |  cd4 dli
KOL Index score: 20807

BACKGROUND: During the storage of cellular components before transfusion, cytokines that may mediate transfusion reactions are released from white cells (WBCs). Adverse effects of transfused cellular blood components therefore depend not only on the number of residual WBCs in blood components, but also on the timing of WBC reduction.

STUDY DESIGN AND METHODS: Febrile nonhemolytic transfusion reactions (FNHTRs), allergic reactions, and other reactions were characterized in recipients of ...

Also Ranks for: Blood Components |  transfusion rbcs |  white cell |  allergic reactions |  wbc reduced
KOL Index score: 18770

In multiple myeloma (MM), migration is necessary for the homing of tumor cells to bone marrow (BM), for expansion within the BM microenvironment, and for egress into the peripheral blood. In the present study we characterize the role of vascular endothelial growth factor (VEGF) and beta(1) integrin (CD29) in MM cell migration. We show that protein kinase C (PKC) alpha is translocated to the plasma membrane and activated by adhesion of MM cells to fibronectin and VEGF. We identify beta(1) ...

Also Ranks for: Endothelial Growth |  protein kinase |  multiple myeloma |  phosphatidylinositol 3 |  pkc alpha
KOL Index score: 17894

Smac, second mitochondria-derived activator of caspases, promotes apoptosis via activation of caspases. Previous studies have shown that c-Jun NH(2)-terminal kinase (JNK) is involved in regulating another mitochondrial protein, cytochrome c during apoptosis; however, the role of JNK in the release of mitochondrial Smac is unknown. Here we show that induction of apoptosis in multiple myeloma (MM) cells is associated with activation of JNK, translocation of JNK from cytosol to ...

Also Ranks for: Mitochondrial Protein |  jnk smac |  apoptosis activation |  mitochondria release |  multiple myeloma
KOL Index score: 17876

PURPOSE: Aurora kinases, whose expression is linked to genetic instability and cellular proliferation, are being investigated as novel therapeutic targets in multiple myeloma (MM). In this study, we investigated the preclinical activity of a small-molecule multitargeted kinase inhibitor, AT9283, with potent activity against Aurora kinase A, Aurora kinase B, and Janus kinase 2/3.

EXPERIMENTAL DESIGN: We evaluated the in vitro antimyeloma activity of AT9283 alone and in combination with ...

Also Ranks for: Aurora Kinase |  mm cells |  antimyeloma activity |  multiple myeloma |  benzimidazoles cell
KOL Index score: 17575

Interleukin-6 (IL-6) is a growth factor for multiple myeloma (MM) cells and can inhibit MM cell apoptosis. Our recent studies show that IL-6 facilitates MM cell growth via phosphorylation of retinoblastoma protein (pRB); however, the effects of IL-6 on those cyclins, cyclin-dependent kinases (CDKs), and CDK inhibitors (CDIs) that are known to regulate phosphorylation of pRB have not been defined in MM cells. In the present report, we cultured MM cell lines and patient cells with IL-6 ...

Also Ranks for: Mm Cells |  g1 growth arrest |  dex il6 |  multiple myeloma |  p21waf1 upregulation

Key People For Multiple Myeloma

Top KOLs in the world
Kenneth **** ********
multiple myeloma mm cells board directors
Robert * ****
multiple myeloma undetermined significance consultancy funding
Sundararajan ******* ********
multiple myeloma consultancy funding undetermined significance
Paul ****** *** **********
multiple myeloma board directors advisory committees
JesusFernando *** *** ******
multiple myeloma consultancy honoraria board directors
Bart ********
multiple myeloma total therapy gene expression

Kenneth Carl Anderson:Expert Impact

Concepts for whichKenneth Carl Andersonhas direct influence:Multiple myeloma,  Mm cells,  Bone marrow,  Myeloma cells,  Multiple myeloma mm,  Multiple myeloma cells,  Mm cell,  Tumor cells.

Kenneth Carl Anderson:KOL impact

Concepts related to the work of other authors for whichfor which Kenneth Carl Anderson has influence:Multiple myeloma,  Bone marrow,  Cancer cells,  Stem cell,  Proteasome inhibitors,  Gene expression,  Monoclonal antibodies.



Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile

Jerome Lipper Multiple Myeloma Disease Center, Dana-Farber Cancer Institute, Harvard Medical School, 02215, Boston, MA, USA | Department of Medical Oncology, Dana-Farber Cancer Institute, Jerome Lipper Center for Multiple Myeloma Research, Harvard Me